Paper · 3587348

Prevalence of ras gene mutations in human colorectal cancers.

Bos JL and 6 others. Nature, 1987. Cited by 1,829 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Prevalence of ras gene mutations in human colorectal cancers. Papers, record 3587348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3587348

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Prevalence of ras gene mutations in human colorectal cancers.; PubMed
Journal: Nature; PubMed
Year: 1987; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/3587348/; PubMed
DOI: https://doi.org/10.1038/327293a0; PubMed
The journal: https://conductscience.org/library/journal-index/0410462; PubMed
Citations, by iCite: 1,829; iCite
Relative citation ratio, by iCite: 41.4; iCite
Revised in PubMed: 2022-03-16; PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Bos JL	J L
2	Fearon ER	E R
3	Hamilton SR	S R
4	Verlaan-de Vries M	M
5	van Boom JH	J H
6	van der Eb AJ	A J
7	Vogelstein B	B

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Colonic Neoplasms	Major topic
Mutation	Major topic
Oncogenes	Major topic
Rectal Neoplasms	Major topic
Adenoma
Carcinoma
Codon
DNA
Humans
Nucleic Acid Hybridization

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
CA35494	NCI NIH HHS	United States	R01CA035494	PubMed and NIH	NIH RePORTER
GM07309	NIGMS NIH HHS	United States		PubMed	PubMed
			R37CA035494	NIH	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by491

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,829 citations.

PMID	Title	Journal	Year	In Papers	Source
42,622,964	Mechanism of neoantigen generation and advances in neoantigen-based immunotherapies in colorectal cancer.	Med Oncol	2026	https://conductscience.org/library/papers/42622964	PubMed
41,596,586	Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.	Int J Mol Sci	2026	https://conductscience.org/library/papers/41596586	PubMed
41,339,549	Decay of driver mutations shapes the landscape of intestinal transformation.	Nature	2026	https://conductscience.org/library/papers/41339549	PubMed
40,736,275	PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.	Oncotarget	2025	https://conductscience.org/library/papers/40736275	PubMed
40,724,985	TIM-3/Galectin-9 Immune Axis in Colorectal Cancer in Relation to KRAS, NRAS, BRAF, PIK3CA, AKT1 Mutations, MSI Status, and the Cytokine Milieu.	Int J Mol Sci	2025	https://conductscience.org/library/papers/40724985	PubMed
40,285,986	NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review.	Inflammopharmacology	2025	https://conductscience.org/library/papers/40285986	PubMed
39,944,579	Chemopreventive strategies for sporadic colorectal cancer: a narrative review.	Transl Gastroenterol Hepatol	2025	https://conductscience.org/library/papers/39944579	PubMed
39,534,512	Targeting carbohydrate metabolism in colorectal cancer - synergy between DNA-damaging agents, cannabinoids, and intermittent serum starvation.	Oncoscience	2024	https://conductscience.org/library/papers/39534512	PubMed
39,430,843	Unveiling the role of KRAS in Chinese colorectal cancer patients: a positive influence on tumor mutational burden.	Transl Cancer Res	2024	https://conductscience.org/library/papers/39430843	PubMed
39,367,162	KRAS mutations detection methodology: from RFLP to CRISPR/Cas based methods.	Funct Integr Genomics	2024	https://conductscience.org/library/papers/39367162	PubMed

1 to 10 of 491

See all 491 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
KRAS	3,845	PubTator's text mining	https://conductscience.org/library/genes/3845

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3587348

GET https://conductscience.org/api/papers/v1/3587348/cited_by?page=2

API reference For AI assistants